Acute myeloid leukemia (AML) is characterized by developmental arrest, which is thought to arise from transcriptional dysregulation of myeloid development programs. Hematopoietic stem and progenitor cells (HSPCs) isolated from human blood are frequently used as a normal comparator in AML studies. Previous studies have reported changes in the transcriptional program of genes involved in proliferation, differentiation, apoptosis, and homing when HSPCs were expanded ex vivo. The intrinsic functional differences between quiescent and dividing CD34 + HSPCs prompted us to determine whether fresh or cytokine-induced cord blood-derived CD34 + HSPCs are a more appropriate normal control compared to AML blasts. Based on principal component analysis and gene expression profiling we demonstrate that CD34 + HSPCs that do not undergo ex vivo expansion are transcriptionally similar to minimally differentiated AML blasts. This was confirmed by comparing the cell cycle status of the AML blasts and the HSPCs. We suggest that freshly isolated CD34 + HSPCs that do not undergo ex vivo expansion would serve as a better control to identify novel transcriptional targets in the AML blast population.
INTRODUCTION
Acute myeloid leukemia (AML) is characterized by a blockade in hematopoietic cell development, which is thought to arise from transcriptional dysregulation of myeloid developmental programs (1). Despite substantial advances in our understanding of the pathophysiology of AML more than half of all patients develop disease that is refractory to intensive chemotherapy. Therefore, new therapeutic targets need to be identified in order to develop new treatments to consolidate current therapy. Such approaches include the discovery of additional gene mutations that are associated with AML; however, most high-frequency gene mutations may have already been identified in AML (2). Further, as recently illustrated by the identification of inappropriate MET signaling in AML, abnormalities in this disease are not necessarily mutated genes (3). Messenger RNA abundances can be used as an alternative strategy for target identification. Normal human hematopoietic stem and progenitor cells (HSPCs) are often used either directly ex vivo as a CD34 + population or expanded in culture as the normal comparator in these studies (4). Freshly isolated HSPCs are mostly in a quiescent state, while in vitro culture promotes proliferation and results in changes in the transcriptional program of genes involved in proliferation, differentiation, apoptosis, and homing, while long-term self-renewal does not occur (5, 6) . Owing to these intrinsic functional differences between quiescent and dividing CD34 + HSPCs, we planned to determine whether fresh or short-term cytokine induction of HSPCs can provide a more appropriate normal control compared to AML blasts.
MATERIALS AND METHODS

CD34 + HSPC Isolation and Culture
Umbilical cord blood (CB) was obtained from fullterm healthy pregnancies at the Maternity Unit of the University Hospital of Wales (UHW) Cardiff, following informed consent. Highly enriched human CD34 + cells (>90%) were derived from CB mononuclear cells using MiniMACS (Miltenyi Biotech, UK) following the manufacturer's instructions and as previously described (7). Confirmation of CB-derived CD34 + HSPC phenotype and purity were assessed by two color immunophenotypic analysis using anti-CD45 PerCP (Biolegend, UK) and CD34-PE (BD Biosciences, UK) coupled with flow cytometry. Freshly isolated CD34 + HSPCs were lysed in TRIzol ® for mRNA analysis (n = 3) (see RNA Isolation). A paired sample was subsequently cultured for 48 h at 1 × 10 5 cells/ml in Iscove's modified Dulbecco medium (IMDM) containing 20% fetal calf serum (FCS) and the following cytokines (from R & D Systems, UK): interleukin 3 (IL-3; 5 ng/ml), IL-6 (10 ng/ml), stem cell factor (SCF; 20 ng/ml), granulocyte-macrophage colony-stimulating factor (GM-CSF; 5 ng/ml), granulocyte colony-stimulating factor (G-CSF; 5 ng/ml), and Flt3 ligand (5 ng/ml) as previously described (7). These cytokine-induced CD34 + HSPCs were then lysed in TRIzol ® described below (n = 3).
Patient Samples
A subset of minimally differentiated (FAB-M1) AML blast samples (n = 6) collected from the bone marrow or peripheral blood of patients enrolled in the NCRI-UK AML clinical trial was used in this study following informed consent (Table 1) . Samples were thawed, and cell viability and cell surface phenotype were analyzed by flow cytometry to support FAB classification. AML patient blast FAB-M1 subtype was confirmed using CD14-PE and CD15-PE (Biolegend). The samples used were >80% viable determined by 7-AAD (Biolegend) and phenotypically had low levels of CD14 and/or CD15 cell surface markers (<10%). Flow cytometric data acquisition and analysis is described below.
Cell Cycle Analysis
CD34 + HSPCs and AML blast cells were washed twice in ice-cold PBS and fixed with 70% ethanol for 30 min on ice and stored at −20 o C. Fixed cells were washed free of alcohol and resuspended in PBS containing 40 µg/ml propidium iodide (Molecular Probes, Netherlands) and 100 µg/ml RNAse type I-AS (Sigma-Aldrich, UK) followed by incubation at 37 o C for 30 min. DNA content was analyzed using flow cytometry (described below).
RNA Isolation and Affymetrix mRNA Gene Expression Profiling (GEP)
Patient AML blast and CD34 + HSPC cells were washed twice in ice-cold PBS and high-quality total RNA was extracted by lysis in TRIzol ® followed by extraction according to the PureLink ® RNA Mini Kit according to the manufacturer's instructions. RNA quality, quantity, and purity were assessed using Agilent RNA 6000 Nano Kit on the Agilent 2100 Bioanalyzer (Agilent Technologies, UK) following the manufacturer's instruction and as previously described (5). Only high-quality RNA [defined as having a RNA integrity number (RIN) >7.0 and A260/280 ratio of ~2.0] was used in Affymetrix GEP. cDNA was generated from 100 ng total RNA using the Ambion WT Expression Kit following the manufacturer's protocol (Applied Biosystems, UK). cDNA was subsequently fragmented and labeled using the Affymetrix GeneChip ® WT Terminal Labelling Kit (Affymetrix, UK) and hybridized to Affymetrix Human Gene 2.0 ST array GeneChip ® . GeneChips ® were subsequently washed and stained using the Affymetrix GeneChip ® Hybridisation, Wash and Stain Kit (Affymetrix) followed by scanning on the GeneChip Scanner 3000. Data were quality controlled using Affymetrix Expression Console. All the work 
Data Analysis
Flow cytometric data were acquired using the BD Accuri TM C6 flow cytometer, and the data were analyzed using FCS Express ® v4 (De Novo Software, USA). Control stained cells were used to determine the antibody threshold for the labeled cells. Debris and ejected nuclei were excluded from the analysis. For DNA content analysis, cell doublets were excluded on the basis of pulse width together with particles having less than 10% of 2 N DNA content, as previously described (8).
Raw Affymetrix intensity measurements of all the probe sets were exported into Partek ® Genomics Suite ® software (PGS), version 6.6 (Partek Inc., USA) for background correction, quantile normalization, and summarization into gene expression level measurements using the Robust Multiarray Averaging (RMA) algorithm. The probe sets were adjusted for GC content and logged using base 2. The microarray analysis was carried out using PGS Gene Expression workflow. Quality control (QC) information from control and experimental probes on the Affymetrix chips was assessed via the QC Metrics of the QA/QC section of the workflow. Following QC, the data were preliminarily explored using principle component analysis (PCA). Significant genes between the contrast groups were calculated with one-way analysis of variance (ANOVA); contrast groups were (i) AML blasts versus freshly isolated CD34 + HSPCs, (ii) AML blasts versus cytokine-induced CD34 + HSPCs, and (iii) freshly isolated CD34 + HSPCs versus cytokine-induced CD34 + HSPCs. Gene lists were created between the different contrast groups based on their significance (>twofold, p < 0.05). These lists were then exported in MetaCore TM (powered by Thomson Reuters GeneGo ® ) and analyzed for pathway enrichment within our data set using Enrichment Analysis workflow.
RESULTS AND DISCUSSION
Initially, we investigated whether the transcriptome (using Affymetrix Human Gene 2.0 ST GeneChips ® ) of freshly isolated (n = 3) (using MACS, Miltenyi Biotech) CD34 + HSPCs was similar to the transcriptome of the same population of cells that had been stimulated with cytokine for 48 h (n = 3), which results in one population doubling.
As shown in Figure 1a , principal component analysis suggests that the overall gene expression profile (GEP) of freshly isolated CD34 + cells is distinct from the same cells after cytokine stimulation. Cytokine induction changed the expression of 1,745 genes of which 989 and 756 genes were over-or underexpressed, respectively, in stimulated cells when compared to their freshly isolated counterparts (> ± twofold; p < 0.05; see Supplemental Material Table  S1 ; available at: https://docs.google.com/spreadsheets/ d/1cvjXXimKNi50B2NDF2RmLo76K1uUUWi7P5s3 CEreYa8/edit?usp=sharing). Pathway and gene ontology analysis of these changes using MetaCore ® showed that the majority of the 10 most significant functional processes involved genes of cell cycle and cell division (Tables 2 and 3 ). Cell cycle genes upregulated in cytokineinduced CD34 + cells included CDK1, CDKN3, CDKN2C, CCNF, CCNE1, CCNE2, CCNB1, CCNB2, CCNA1, CNNA2, and CCNF. Chemokines and growth factors such as CCL1 and IL1RL1, elastase (CELA2B), phosphoserine aminotransferase (PSAT1) were also changed in cytokineinduced HSPCs.
We next analyzed minimally differentiated AML (FAB-M1, n = 6). This subtype has little developmental heterogeneity and would also be developmentally matched to HSPCs. We found that the AML expression profile more closely resembled the transcriptome of freshly isolated HSPCs (Fig. 1a) . Of the 494 genes that were different between these two groups (> ± twofold; p < 0.05), 396 genes had a higher expression level in fresh HSPCs. These genes were mainly involved in cellular and system developmental processes (such as SNF2L1, AKT, SNF2L1, PAX5, DCHS1, PAM, DR6, HMGA2, SERPINE2, CNN3) and regulation of localization (e.g., VMAT2, DR6, GPCRs, HLA-DRB1, TBCD4). Genes more highly expressed in AML blasts were associated with cell developmental processes (Table 2 ) such as cell differentiation (HOX family members, PBX and WT1), regulating the homotypic cellcell adhesion and negatively regulating the platelet aggregation (PKCd, b-adrenergic receptors, and GPCRs). As expected from the PCA, the number of gene expression differences between AML blasts and cytokine-treated HSPCs was much greater with 2,676 differently expressed genes (> ± twofold; p < 0.05). Similar to the differences between freshly isolated and cytokine-induced CD34 + cells, the functional pathways that changed when cytokine-induced CD34 + cells were compared to AML were also related to cell cycle and cell division (Tables 2 and 3) . Genes more highly expressed in AML blast samples compared to dividing HSPCs involved changes in regulation of transcription and gene expression (e.g., JMY, KLF7, PP2Aa, NF-AT5, MDM4, HMGB1, IRF1) or regulation of RNA and other cellular and metabolic processes (e.g., ZNF222, CCL5, TRIP8, CCND2).
Of particular note, E2F family members such as E2F1, E2F2, E2F4, E2F7, and E2F8, which regulate the expression of genes involved in differentiation, proliferation, development, and apoptosis (9), were highly expressed in cytokine-induced CD34
+ HSPCs compared to AML blast samples and unstimulated CD34 + HSPCs, thus confirming an induction of differentiation signature due to the cytokines used. In contrast, AML blasts highly expressed genes (compared to HPSCs) involved in notch signaling including NFKB1A, and genes involved in several signal transduction pathways such as TRAF6, TLR2, IL3RA, IL11RA, and IL13RA, which are known to be frequently overexpressed in AML. b-Adrenergic receptors, known to be involved in several cancers (10), were also highly expressed in the AML patient blasts as were genes involved in the negatively regulating cell morphogenesis instrumental to cell differentiation (GO: 0010771) (PPP2CA, ULK1, RAPGEF2, and ARHGAP4). Most of the genes that were expressed in patients were involved in various phases of the cell cycle process and various immune responses compared to cytokine-induced and unstimulated CD34 HSPCs, respectively (see Supplementary Material Table  S2 and Table S3 ; available at: https://docs.google.com/ spreadsheets/d/1cvjXXimKNi50B2NDF2RmLo76K1uU UWi7P5s3CEreYa8/edit?usp=sharing).
The GEP data above suggest that when CD34 + cells are stimulated with cytokine for 48 h, the transcriptional program of the cells invokes changes in cell cycle/division transcription as would be expected. AML blasts have a transcriptional program similar to freshly isolated CD34 + cells, which are withdrawn from cell cycle. To support these data, we analyzed the cell cycle status of each of the populations using flow cytometry and analysis of DNA content. As shown in Figure 1b , the majority of AML cells and freshly isolated CD34 + HSPCs were in G 0 /G 1 . In contrast, over 50% of the cytokine-induced HSPCs were in S and G 2 M phases. This is in concordance with the work of Lucotti et al. (11) , where they compared the cell cycle status of cord blood-derived freshly harvested and cultured (up to 24 h) CD34 + HSPCs. Total Genes refers to the total number of genes in the GO process of the Human Gene 2.0 ST genome. In Data refers to the number of genes from the dataset that are involved in the GO process. p Value ranks the GO process based on a probability to have the given value of actual or higher (or lower for negative z score). GO Processes are ranked according to false discovery rate (FDR) ensuring that no more than 5% of significant terms are false positive. The GO processes are not mutually exclusive in terms of containing a gene.
This study shows for the first time that the GEP of CD34 + cells that do not undergo ex vivo expansion are the best match for the GEP of minimally differentiated AML blasts and would serve as a better control to identify novel targets in the AML blast population. AML blast cells are usually banked or cryopreserved for preclinical studies and exhibit a quiescent phenotype upon thawing. However, a study by Hess et al. (12) found no significant differences in the GEP of fresh versus frozen AML blasts. Thus, freshly isolated, quiescent CD34 + HSPCs are the more appropriate control for transcriptomic studies for minimally differentiated AML blasts. This would likely also be the case for other "omic" technologies where the analysis is much more demanding of the amount of biologic material, posing a significant limitation in these studies. Nonetheless, there are opportunities for the use of the data derived to target analysis of specific proteins that may be differentially expressed between apparently normal quiescent primitive hematopoietic cells and their AML counterparts; this can be achieved with new technologies such as micro-Western blotting (13). In the present study genes such as adrenoreceptors, EVI1 (regulates self-renewal in hematopoietic stem cell compartment), Homeobox genes (regulate development) are found to be differentially expressed. Using immunocytohistochemistry or micro-Western blotting we can gain insight into the changing patterns of such expression between these populations knowing we have now identified an appropriate control population. Total Genes refers to the total number of genes in the pathway of the Human Gene 2.0 ST genome. In Data refers to the number of genes from the dataset that are involved in the pathway. p Value ranks the canonical pathways based on a probability to have the given value of actual or higher (or lower for negative z score). Pathways are ranked according to false discovery rate (FDR) ensuring that no more than 5% of significant terms are false positive. The pathways are not mutually exclusive in terms of containing a gene.
